DanTVoglMDMSCE

Hematologic Oncology

Assistant Professor of Medicine

Dr. Vogl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3400 Civic Center Blvd
Philadelphia, PA 19104
Phone+1 215-615-6508

Fax+1 215-615-5887

University of Pennsylvania Perelman School of MedicineMSCE, Clinical Trials Methodology, 2009
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2003 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2000 - 2003
Weill Cornell MedicineClass of 2000

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

PubMed

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.
Dan T Vogl, Shebli Atrash, Sarah A Holstein, Omar Nadeem, Don M Benson Jr
Blood. 2024-12-04
Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis.
Margaret Stalker, Alfred Garfall, Adam Cohen, Dan T Vogl, Mia Djulbegovic
European Journal of Haematology. 2024-11-17
Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma.
Omar Elghawy, Saarang Deshpande, Jonathan Sussman, Alfred Garfall, Adam Cohen
Bone Marrow Transplantation. 2024-10-30

Journal Articles

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers
Matthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine

Abstracts/Posters

Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Dan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Dan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
Dan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Dan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Karyopharm’s Selinexor Combination for Multiple Myeloma Unlikely to See Second-Line Use Despite Likely FDA ApprovalDecember 18th, 2020
$Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting$
Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual MeetingSeptember 14th, 2018
Novel Agents, Combos Excite in Multiple MyelomaNovember 28th, 2017
Join now to see all